Haemophilia is a type of bleeding disorder in which the blood does not clot properly. Appropriate management helps people with haemophilia to live full, healthy and active lives, with the same opportunities as anyone else. 

Since 2006, Sobi has been working with Bioverativ and has developed a new generation of haemophilia treatments, which are manufactured in state-of-the-art facilities. Sobi is providing recombinant factor treatments to people in our territory - Europe, most markets in the Middle East and North Africa.

Through our partnership with Bioverativ and the wider haemophilia community, we are actively seeking to find solutions for the challenges facing people with haemophilia.